RSHN cancellation of reverse split RushNet Inc. C
Post# of 103012
(Total Views: 143)
Posted On: 06/09/2021 1:20:44 PM
RSHN cancellation of reverse split
RushNet Inc. Cancellation of Proposed Reverse Split
Press Release | 06/09/2021
ALPHARETTA, GA / ACCESSWIRE / June 9, 2021 / RushNet, Inc. (OTC PINK:RSHN) ("RushNet"
with merger/acquisition target heliosDX, is pleased to announce the official cancelation of the proposed Reverse Split (RS). The company will file with the Colorado Secretary of State to reflect such cancelation.
About HeliosDx:
heliosDX is a National Independent Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.
Contact: Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com (Under Development)
Twitter: @dx_helios
https://www.otcmarkets.com/stock/RSHN/news/Ru...?id=306586
RushNet Inc. Cancellation of Proposed Reverse Split
Press Release | 06/09/2021
ALPHARETTA, GA / ACCESSWIRE / June 9, 2021 / RushNet, Inc. (OTC PINK:RSHN) ("RushNet"
with merger/acquisition target heliosDX, is pleased to announce the official cancelation of the proposed Reverse Split (RS). The company will file with the Colorado Secretary of State to reflect such cancelation. About HeliosDx:
heliosDX is a National Independent Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.
Contact: Ashley Sweat
asweat@heliosdx.com
www.heliosdx.com (Under Development)
Twitter: @dx_helios
https://www.otcmarkets.com/stock/RSHN/news/Ru...?id=306586
(0)
(0)Scroll down for more posts ▼